INVERSAGO-PHARMA-INC.
29.9.2020 14:02:30 CEST | Business Wire | Press release
Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has initiated a Phase 1 clinical trial of INV-101, the Company’s peripherally-acting CB1 blocker, which is being developed for the treatment of Prader-Willi syndrome (PWS) and non-alcoholic steatohepatitis (NASH).
The trial will evaluate the safety, tolerability and pharmacokinetics of INV-101. Recruitment is ongoing and will enroll healthy participants in Canada, from 18 to 55 years old. Subjects will initially be randomized to receive a single dose of placebo or one of 5 dose levels of INV-101.
“With the launch of this first-in-human trial, Inversago is now a clinical-stage company, and confirms its lead in the comeback of small molecule peripheral CB1 blockers”, said François Ravenelle, PhD, CEO and founder of Inversago Pharma.
“Dosing of our first patient with INV-101 represents an important milestone to accomplish the Company’s vision: offering a potentially meaningful therapeutic option to underserved patient populations, like in PWS and NASH" said Carlo Incerti, M.D., Chairman of the Board of Inversago. "This study is the first step in the clinical development of our peripherally-acting CB1 blockers, and we expect it to provide important information about its safety and pharmacokinetics profile", concluded Dr. Incerti.
The Company’s second program, INV-202, is presently in IND-enabling preclinical studies, while other programs are in earlier stages of development. With its current pipeline, Inversago is well positioned to fully exploit peripheral CB1 blockade for a wide range of underserved metabolic indications with differentiated products.
About INV-101
INV-101 is a first-in-class, small molecule CB1 inverse agonist / antagonist being developed by Inversago for the treatment of PWS and NASH. It is specifically designed to interact with peripheral CB1 receptors located in the gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers. The peripheral CB1 blockade is a well-documented pathway, linked to many clinically meaningful metabolic benefits.
About Inversago Pharma
Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D) and diabetic nephropathy. For more information, visit inversago.com .
Picture of our CEO and company logotype available for download at: inversago.com/en/media/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200929005408/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GenNx360 Capital Partners Closes Fourth Flagship Fund at $865 Million27.8.2026 14:30:00 CEST | Press release
Fund IV success is the result of two decades of proven performance backing lower middle market industrial services and business services companies GenNx360 Capital Partners (“GenNx360” or “the Firm”), a New York City-based private equity firm investing in U.S. lower middle market industrial services and business services companies, today announced the successful closing of GenNx360 Capital Partners IV, L.P. (“Fund IV” or “the Fund”), with $865 million in commitments, exceeding its target. Fund IV is the largest fund raised in GenNx360’s history. Fund IV was supported by a diverse group of existing and new investors including leading pensions, asset managers, insurance companies, foundations, and family offices, reflecting conviction in the firm’s disciplined investment approach, operational value creation model, and tenured, diverse team. Fund IV will continue GenNx360’s differentiated strategy of partnering with lower middle market founders and management teams to scale essential serv
Alipay Ant Forest Turns 700 Million Users’ Daily Green Actions into 700 Million Trees Over a Decade of Technology-enabled Environmental Program27.8.2026 14:02:00 CEST | Press release
Alipay Ant Forest, Ant Group’s green initiative that encourages people to participate in environmental protection through simple, everyday low-carbon actions, today announced that more than 700 million users across China have joined the program as of August 2026. Together, they have helped support the planting of over 700 million trees, contributing to ecological restoration efforts in some of China’s most arid and environmentally fragile regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827995848/en/ Before (2019) and after (2026) comparison of Ant Forest Project No. 464 in Inner Mongolia. Launched in 2016 within the Alipay app, Ant Forest transforms individual environmental choices into collective climate action. When users make greener lifestyle choices, such as taking public transportation, cycling, paying bills online to avoid paper invoices, or choosing digital services, they earn virtual “green energy points”
Visa Expands Support for its Clients and the Industry as Organizations Navigate New AI Era of Cybersecurity27.8.2026 14:00:00 CEST | Press release
Latest Visa Vulnerability Agentic Harness release moves AI-powered cyber risk management from discovery to validated remediationNew services from Visa Consulting & Analytics help clients identify the vulnerabilities that matter most and act before bad actors do Visa (NYSE: V) today announced enhancements to its cybersecurity portfolio to help organizations identify and fix vulnerabilities more effectively. Unveiling the next evolution of the Visa Vulnerability Agentic Harness (VVAH), its open-source, model-agnostic framework, Visa is helping organizations significantly reduce the Mean Time to Adapt (MTTA), the time between discovery and resolution of attack paths, with some resolutions shrinking from weeks to hours. And to help clients navigate this evolving threat landscape, Visa also announced the expansion of its Visa Consulting & Analytics (VCA) Cybersecurity Advisory Practice with new advisory services designed to help clients assess risk, prioritize remediation efforts and streng
Omilia Appoints Michael Weiss as Vice President, DACH27.8.2026 14:00:00 CEST | Press release
Five9 veteran joins Omilia to lead go-to-market strategy across Germany, Austria, and Switzerland as the region's most regulated enterprises look past first-generation automation Omilia, a global leader in Self-Learning Agentic CX, today announced the appointment of Michael Weiss as Vice President, DACH. Weiss will lead Omilia's go-to-market strategy across Germany, Austria, and Switzerland, as the company expands its European footprint, with a focus on regulated sectors where enterprise demand for AI that moves past pilot-stage containment is accelerating. In his new role, Weiss will be responsible for enterprise sales, partner development, and go-to-market execution across DACH, building the team and customer relationships needed to scale Omilia's presence in a market where large, heavily regulated enterprises have historically been slow to move off legacy IVR and first-generation AI. Weiss brings more than two decades of enterprise sales leadership in SaaS, cloud, and customer exper
Perma-Pipe Announces Closing of Global Credit Facility of Up to $139 Million27.8.2026 13:47:00 CEST | Press release
New Credit Facility Enhances Global Financial Flexibility to Support Growth Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) (“Perma-Pipe” or the “Company”), a leading global provider of engineered piping and leak detection solutions for energy, infrastructure and industrial markets, today announced the closing of a new global credit facility with J.P. Morgan consists of a $75.0 million revolving credit facility and a $14.0 million term loan facility, and allows the Company access to an additional $50.0 million in incremental capacity. The new facility replaces and consolidates multiple existing credit facilities maintained by the Company and its subsidiaries across various jurisdictions, creating a more streamlined and centralized financing structure for Perma-Pipe’s global operations. It also provides Perma-Pipe with significantly increased financial capacity, enhanced liquidity and greater flexibility to support working capital requirements, letters of credit, strategic invest
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom